A phase II study of the VEGFR- and FGFR-inhibitior Dovitinib (TKI258) in patients with refractory advanced or metastatic renal cell cancer previously treated with VEGFR- or mTOR-targeted therapy
Document type:
Meeting Abstract
Author(s):
Grunwald, V; Retz, M; Fenner, M; Wang, Y; Chang, J; Kay, A; Zuern, C; Gschwend, J